In addition, comprehensive studies involving cell lines, murine models, and human specimens are necessary to more fully define the timing and mechanisms of FILIP1L downregulation during LUAD development, and to determine the potential utility of FILIP1L promoter methylation as a biomarker of aggressive phenotype and poor prognosis in patients with these neoplasms. Here, FILIP1L is linked to neoplasm.